Company LungLife AI, Inc.

Equities

LLAI

USU5500L1045

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Diagnostics & Testing

Market Closed - London S.E. Other stock markets 09:05:14 14/05/2024 pm IST			5-day change	1st Jan Change
25.5 ^GBX	0.00%		-1.92%	-44.57%

05/04	Transcript : LungLife AI, Inc., 2023 Earnings Call, Apr 05, 2024
04/04	LungLife reports narrowed losses in year of "considerable achievement"	AN

LungLife AI, Inc. is a developer of clinical diagnostic solutions for lung cancer. The Company is engaged in the development and commercialization of its lung cancer early detection test. Using a minimally invasive blood draw, its LungLB test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.

Number of employees: 15

GBP in Million	2022	Weight	2023	Weight	Delta
Royalty 100.0 %	0	100.0 %	0	100.0 %	+89.93%

GBP in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	0	100.0 %	0	100.0 %	+89.93%

Managers	Title	Age	Since
Paul Pagano CEO	Chief Executive Officer	40	-
David Anderson DFI	Director of Finance/CFO	61	-
William M. Strauss CTO	Chief Tech/Sci/R&D Officer	-	-
Michael Donovan CTO	Chief Tech/Sci/R&D Officer	70	-
Rebecca Reed LAW	General Counsel	-	-
Lara Baden PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Gordon Davis CHM	Chairman	67	08/21/08
Andrew Boteler BRD	Director/Board Member	58	08/21/08
David Anderson DFI	Director of Finance/CFO	61	-
James McCullough BRD	Director/Board Member	56	01/19/01
Sara Barrington BRD	Director/Board Member	57	08/21/08
Paul Pagano CEO	Chief Executive Officer	40	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	30,658,603	15,724,173 ( 51.29 %)	0	51.29 %

Name	Equities	%	Valuation
Unicorn Asset Management Ltd. 6.867 %	1,750,000	6.867 %	624 505 p
Lombard Odier Asset Management (Europe) Ltd. 4.977 %	1,268,363	4.977 %	452 628 p
Maven Capital Partners UK LLP 0.4144 %	105,619	0.4144 %	37 691 p
David Anderson 0.0476 %	12,123	0.0476 %	4 326 p
Paul Pagano 0.0476 %	12,123	0.0476 %	4 326 p

LungLife AI, Inc.

2545 West Hillcrest Drive Suite 140

91320, Thousand Oaks

+805 409 9868

http://www.lunglifeai.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.255 GBP

Average target price

2.2 GBP

Spread / Average Target

+762.75%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Diagnostics & Testing

	1st Jan change	Capi.
LUNGLIFE AI, INC.	-44.57%	9.81M
EXACT SCIENCES CORPORATION	-28.14%	10.26B
IOVANCE BIOTHERAPEUTICS, INC.	+32.66%	3.04B
GUARDANT HEALTH, INC.	-7.99%	2.94B
BGI GENOMICS CO., LTD.	-13.62%	2.19B
VERACYTE, INC.	-16.72%	1.72B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+64.81%	1.4B
CAREDX, INC	+27.67%	780M
SEEGENE, INC.	-2.18%	736M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-18.75%	560M

Bio Diagnostics & Testing